Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Paragon 28 Inc (FNA) is a leading innovator in foot and ankle orthopedic devices, specializing in surgical solutions that enhance patient outcomes. This news hub provides investors and healthcare professionals with essential updates on the company’s financial performance, product developments, and industry leadership.
Access real-time announcements including quarterly earnings reports, FDA-cleared device launches, and strategic partnerships with surgical institutions. Our curated collection features regulatory milestones, clinical trial results, and executive commentary – all critical for understanding FNA’s position in the $5B+ global foot and ankle device market.
Key updates cover innovative implant systems, surgeon training initiatives, and manufacturing expansions that demonstrate Paragon 28’s commitment to advancing orthopedic care. Bookmark this page for verified updates on procedural innovations like fracture fixation solutions and deformity correction technologies.
A class action securities lawsuit has been filed against Paragon 28 (NYSE:FNA), a medical device company, in the U.S. District Court for the District of Colorado. The lawsuit alleges that the company and certain officers made false and misleading statements regarding financial statements and internal controls between May 5, 2023 and September 20, 2024. Cohen Milstein Sellers & Toll PLLC is urging affected shareholders who suffered significant losses during this period to contact them by November 29, 2024 to potentially serve as lead plaintiff. Investors are not required to file as lead plaintiff to participate in any potential recovery.
Paragon 28, a medical device company in the foot and ankle orthopedic market, reported its Q3 2024 financial results and raised its 2024 net revenue guidance. The company recorded global net revenue of $62.3 million, marking 18.1% reported growth compared to the prior year. U.S. net revenue was $51.2 million, a 14.8% increase, while international net revenue was $11.2 million, up 35.7%. Despite a net loss of $12.3 million, this was an improvement from the $11.2 million loss in Q3 2023. Gross margin decreased to 74.1% from 77.4%. Operating expenses rose 6.3% to $54.6 million. Adjusted EBITDA turned positive to $0.4 million. Free Cash Flow improved by 69.5% year-over-year. The company raised its 2024 net revenue guidance to $252-$256 million, representing 16.5%-18.3% growth.
Rigrodsky Law has initiated an investigation into Paragon 28 (NYSE:FNA) regarding potential claims against its officers and directors. The investigation focuses on whether the company and its leadership issued materially misleading information or failed to disclose material information to investors concerning financial outlook and internal controls over financial reporting. The investigation covers shareholders who acquired Paragon shares on or before May 5, 2023. Affected shareholders can learn more about their rights at no cost through Rigrodsky Law's website or by contacting their representative.
Paragon 28 (NYSE: FNA), a leading medical device company focused on the foot and ankle orthopedic market, has announced it will report its third quarter 2024 financial results after market close on Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time on the same day to discuss the results.
Investors can participate in the conference call by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. The webcast will be available on the 'Investors' section of Paragon 28's website at ir.paragon28.com and will be archived for replay for at least 90 days after the event.
Paragon 28 (NYSE: FNA) has launched the Phantom® Fibula Nail System, offering surgeons a less invasive option for treating ankle fractures. This system has shown fewer soft tissue complications, implant removals, and fracture nonunion compared to traditional plate and screw fixation. The system includes innovative features such as:
- Instrumentation for anatomic reduction and proper implant placement
- An Entry K-Wire Guide for correct starting point identification
- A Curved Reamer Guide for proper implant angle
- Screws that thread into the nail
- An expandable proximal locking mechanism
- Compatibility with Paragon 28's syndesmotic implant options
The Phantom® Fibula Nail System is delivered in one surgical tray with sterile packed implants, simplifying surgical workflow and inventory management. It joins Paragon 28's extensive foot and ankle fracture portfolio.
Paragon 28 (NYSE: FNA) has introduced a novel Right-Angle Drill for its APEX 3D™ Total Ankle Replacement System. This new tool is designed to improve tibia preparation before implanting the APEX 3D™ tibia implant. The drill uses a linear guide to precisely create vertical holes in the tibia, ensuring ideal peg placement and a stable implant interface.
This addition is part of a series of instrumentation enhancements to the APEX 3D™ system, including recently released Polishing Blocks, Square Tip Drill, and next-generation Off-Set Impaction Handle. These improvements aim to enhance tibia preparation, contributing to the long-term success of ankle replacements and improving surgeon experience and patient outcomes.
Paragon 28 (NYSE: FNA) has launched the R3FLEX™ Stabilization System, designed to restore stability to ankle syndesmosis after injuries from ankle fractures or high ankle sprains. The system allows surgeons to precisely adjust and visualize tension during repair with a simple handle turn. Key features include:
- Restores soft tissue to a more natural anatomy
- Mitigates arthritic response
- Minimizes risk of hardware removal
- Tibial implant rests on internal surface, reducing risk to saphenous nerve and vein
- Strong repair construct less susceptible to elongation
- Allows controlled micromotion similar to uninjured state
- Delivered in a single sterile kit for simplified workflow
The R3FLEX™ system enhances Paragon 28's soft tissue portfolio, providing a comprehensive solution for foot and ankle soft tissue needs.
Paragon 28 (NYSE: FNA) has launched the SMART28℠ Case Management Portal, a platform leveraging AI for coordinating patient-specific surgical plans. This marks the first major release in Paragon 28's SMART28℠ ecosystem, aimed at improving foot and ankle treatments through advanced technologies.
The portal's first module, SMART Bun-Yo-Matic℠, focuses on bunion correction. It offers unique features like 3D anatomy visualization from X-rays and AI-driven algorithms for tailored surgical plans. Dr. Cesar De Cesar Netto, an early user, praised the system's precision in Hallux Valgus surgery.
CEO Albert DaCosta emphasized the portal's significance for the future of foot and ankle surgery, highlighting its efficiency in 3D procedure planning and precise implementation. The SMART28℠ Case Management Portal is set to expand with additional modules for various foot and ankle conditions.
Paragon 28 (NYSE: FNA) has appointed Chadi Chahine as CFO and EVP of Supply Chain Operations, effective August 5, 2024. The company reported Q2 2024 financial results, with global revenue of $61.0 million, representing 19.6% growth. Key highlights include:
- Narrowed 2024 net revenue guidance to $249-$255 million
- Initiated operational efficiency strategy, including 7% workforce reduction
- Q2 gross margin at 75.0%, down from 77.3% in Q2 2023
- Net loss of $13.8 million in Q2 2024
- Adjusted EBITDA loss of $3.0 million, an improvement from $5.4 million loss in Q2 2023
The company also announced a restatement of financial statements for FY 2023 and Q1 2024 due to material accounting errors in inventory calculations.
Paragon 28 (NYSE: FNA), a leading medical device company focused on the foot and ankle orthopedic market, has announced it will report its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time to discuss the results. Investors can join the call by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 389675.
Additionally, Paragon 28's management team will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 14, at 8:00 a.m. Eastern Time. Both events will be webcast live and archived on the company's investor relations website at ir.paragon28.com.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
